JP2021531756A5 - - Google Patents

Info

Publication number
JP2021531756A5
JP2021531756A5 JP2021500823A JP2021500823A JP2021531756A5 JP 2021531756 A5 JP2021531756 A5 JP 2021531756A5 JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021531756 A5 JP2021531756 A5 JP 2021531756A5
Authority
JP
Japan
Prior art keywords
domain
igg1
domain monomer
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041324 external-priority patent/WO2020014429A2/en
Publication of JP2021531756A publication Critical patent/JP2021531756A/ja
Publication of JP2021531756A5 publication Critical patent/JP2021531756A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500823A 2018-07-11 2019-07-11 CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021531756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696746P 2018-07-11 2018-07-11
US62/696,746 2018-07-11
PCT/US2019/041324 WO2020014429A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Publications (2)

Publication Number Publication Date
JP2021531756A JP2021531756A (ja) 2021-11-25
JP2021531756A5 true JP2021531756A5 (https=) 2022-07-20

Family

ID=69142497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500823A Withdrawn JP2021531756A (ja) 2018-07-11 2019-07-11 CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20250346676A1 (https=)
EP (1) EP3820517A4 (https=)
JP (1) JP2021531756A (https=)
KR (1) KR20210042324A (https=)
CN (1) CN113164590A (https=)
AU (1) AU2019302662A1 (https=)
BR (1) BR112021000391A2 (https=)
CA (1) CA3105985A1 (https=)
IL (1) IL279987A (https=)
MX (1) MX2021000290A (https=)
WO (1) WO2020014429A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
MX2024008641A (es) * 2022-01-12 2024-07-24 Biomolecular Holdings Llc Anticuerpos tetraedricos.
CN121100128A (zh) * 2023-04-24 2025-12-09 百图生科(苏州)智能科技有限公司 异源多聚体多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP3511343A1 (en) * 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs

Similar Documents

Publication Publication Date Title
JP2021532085A5 (https=)
JP2021530498A5 (https=)
JP2018046872A5 (https=)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2020514301A5 (https=)
JP2021531756A5 (https=)
JP2020018311A5 (https=)
JP2023022186A5 (https=)
JP2020184996A5 (https=)
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
JP2019059786A5 (https=)
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
RU2007139953A (ru) Антитела к ccr5 и их применение
JP2021530989A5 (https=)
RU2007111941A (ru) АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА Fc-ГАММА RIIB И ИХ ПРИМЕНЕНИЕ
DK2036926T3 (da) Enkeltkædet molekyle, der kan binde til flere antigener, dettes fremstilling og anvendelse
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
JP2020508655A5 (https=)
RU2019119442A (ru) Новый коньюгат аманитина
JP2017052784A5 (https=)
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
EP2135879A3 (en) Ligand
DE602006003695D1 (de) Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
JP2009225799A5 (https=)